Fate of Lymphocytes after Withdrawal of Tofacitinib Treatment

Tofacitinib (Tofa) is an inhibitor of Janus Kinase 3, developed for the treatment of autoimmune diseases and for the prevention of transplant rejection. Due to its selective action on proliferating cells, Tofa can offer a way to block T cell activation, without toxic effects on resting cells. Howeve...

Descripción completa

Detalles Bibliográficos
Autores principales: Piscianz, Elisa, Valencic, Erica, Cuzzoni, Eva, De Iudicibus, Sara, De Lorenzo, Elisa, Decorti, Giuliana, Tommasini, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3887061/
https://www.ncbi.nlm.nih.gov/pubmed/24416411
http://dx.doi.org/10.1371/journal.pone.0085463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3887061/
https://www.ncbi.nlm.nih.gov/pubmed/24416411
http://dx.doi.org/10.1371/journal.pone.0085463

Ejemplares similares